Karnofsky Performance Scale Calculator
Assess patient functional status using the Karnofsky Performance Status scale (0-100). Enter values for instant results with step-by-step formulas.
Formula
KPS = Clinician-assessed functional status score (0-100, increments of 10)
The Karnofsky Performance Status scale rates patient functional capacity from 0 (dead) to 100 (normal function, no complaints). Scores are assigned in increments of 10 based on the patient ability to perform normal activities, self-care requirements, and need for institutional or medical assistance.
Worked Examples
Example 1: Post-Surgical Brain Tumor Patient
Problem: A 55-year-old glioblastoma patient, 3 weeks post-craniotomy, can care for himself but cannot return to work as an engineer. He has minor residual left hand weakness. Weight loss is 4% over 2 months. Assess KPS.
Solution: Patient cares for self but unable to do normal work activity = KPS 70\nECOG equivalent = 1\nFunctional category: Unable to work but living at home\nWeight loss 4% = Low nutritional risk\nPrognostic group for GBM with KPS 70+ = More favorable RPA class
Result: KPS 70 | ECOG 1 | Candidate for standard Stupp protocol (radiation + temozolomide). Favorable prognostic category.
Example 2: Advanced Cancer with Declining Function
Problem: A 68-year-old with metastatic pancreatic cancer requires help with bathing and dressing. She spends about 60% of her day in bed. Weight loss is 15% over 3 months. Assess KPS and care recommendations.
Solution: Requires considerable assistance = KPS 40-50\nSpends >50% in bed = KPS 40 (disabled, requires special care)\nECOG equivalent = 3\nWeight loss 15% = Severe malnutrition risk\nPrognostic group = Poor\nHospice consideration threshold met (KPS <= 70)
Result: KPS 40 | ECOG 3 | Poor prognosis. Best supportive care recommended. Hospice referral and palliative care consultation indicated.
Frequently Asked Questions
What is the Karnofsky Performance Status scale?
The Karnofsky Performance Status (KPS) scale is a standardized assessment tool that measures a patient's ability to perform ordinary tasks and activities of daily living. Developed by David Karnofsky and Joseph Burchenal in 1949, it is one of the oldest and most widely used functional assessment tools in oncology. The scale ranges from 0 (dead) to 100 (fully functional with no complaints) in increments of 10. The KPS is divided into three broad functional categories: patients who can carry on normal activity (80-100), patients who are unable to work but can live at home (50-70), and patients who cannot care for themselves (0-40). This tripartite division helps clinicians quickly categorize patients for treatment planning and prognostic discussions.
How does the Karnofsky scale differ from the ECOG scale?
The Karnofsky Performance Status scale uses an 11-point scale (0-100 in increments of 10) while the ECOG scale uses a simpler 6-point scale (0-5). The KPS provides greater granularity, allowing clinicians to detect more subtle changes in functional status over time. For example, a patient deteriorating from KPS 80 to KPS 70 represents a meaningful functional decline that would both fall under ECOG 1. The ECOG scale is more commonly used in modern clinical trial protocols because its simplicity leads to better inter-observer agreement. However, the KPS remains preferred in neuro-oncology, palliative care, and radiation oncology where finer discrimination of functional changes is clinically important. Both scales are validated and can be approximately converted between each other for comparison purposes.
What is the prognostic significance of the Karnofsky score?
The Karnofsky Performance Status is one of the strongest independent predictors of survival across virtually all cancer types. In brain tumors, KPS is a mandatory component of recursive partitioning analysis (RPA) classification and significantly influences treatment decisions. Studies in glioblastoma show that KPS greater than or equal to 70 is associated with median survival approximately twice that of patients with KPS below 70. In lung cancer, each 10-point decrease in KPS is associated with approximately 10-20% increase in mortality risk. For palliative care populations, KPS below 50 is associated with a median survival of approximately 8-12 weeks, while KPS below 30 typically indicates a prognosis of days to weeks. The prognostic value of KPS extends beyond oncology and is used in predicting outcomes in HIV/AIDS, organ transplantation, and geriatric medicine.
What are the limitations of the Karnofsky scale?
The KPS has several well-recognized limitations despite its long history and widespread use. The scale relies on subjective clinician judgment, leading to inter-observer variability particularly at intermediate scores (50-70). The 10-point increments may miss clinically meaningful changes that fall between standard scores. Age-related baseline functional differences are not accounted for, as an 80-year-old and a 40-year-old with identical functional capacities would receive the same score despite very different clinical implications. Cultural and socioeconomic factors influence functional expectations and may bias assessments. The scale was developed in 1949 and does not reflect modern treatment paradigms such as oral targeted therapies or immunotherapies that patients can take at home. Cognitive impairment and psychological symptoms are not adequately captured by the scale. Despite these limitations, KPS remains valuable due to its simplicity, widespread familiarity, and extensive validation data.
Can I use Karnofsky Performance Scale Calculator on a mobile device?
Yes. All calculators on NovaCalculator are fully responsive and work on smartphones, tablets, and desktops. The layout adapts automatically to your screen size.
Can I share or bookmark my calculation?
You can bookmark the calculator page in your browser. Many calculators also display a shareable result summary you can copy. The page URL stays the same so returning to it will bring you back to the same tool.